drugset

drugset / Trial / NCT03071926

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

NCT03071926 ↗

Phase 2 Unknown 46 enrolled Fudan University

NaSingle-groupOpen-labelTreatment

Summary

Metronomic PLD in Patients with Primary Endocrine Resistant ABC

Timeline

Start: 2017-03-01
Primary completion: 2022-12-01
Completion: 2022-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Doxorubicin	Other / unclassified	20 mg	—

Indications